Almirall SA
MAD:ALM

Watchlist Manager
Almirall SA Logo
Almirall SA
MAD:ALM
Watchlist
Price: 8.15 EUR -0.24% Market Closed
Market Cap: 1.7B EUR
Have any thoughts about
Almirall SA?
Write Note

Almirall SA
Inventory

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Almirall SA
Inventory Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Inventory CAGR 3Y CAGR 5Y CAGR 10Y
Almirall SA
MAD:ALM
Inventory
€167.1m
CAGR 3-Years
10%
CAGR 5-Years
10%
CAGR 10-Years
6%
Laboratorios Farmaceuticos ROVI SA
MAD:ROVI
Inventory
€355.5m
CAGR 3-Years
17%
CAGR 5-Years
N/A
CAGR 10-Years
19%
F
Faes Farma SA
MAD:FAE
Inventory
€138.9m
CAGR 3-Years
9%
CAGR 5-Years
17%
CAGR 10-Years
18%
Laboratorio Reig Jofre SA
MAD:RJF
Inventory
€66.7m
CAGR 3-Years
13%
CAGR 5-Years
15%
CAGR 10-Years
39%
No Stocks Found

Almirall SA
Glance View

Market Cap
1.7B EUR
Industry
Pharmaceuticals

Almirall SA, a venerable player in the pharmaceutical industry, has its roots deeply embedded in the Spanish landscape where it began its journey in 1943. With a commitment to innovation and a keen focus on dermatology, the company has carved out a significant niche for itself. Almirall's core strategy revolves around the development, manufacturing, and commercialization of its proprietary medications, particularly those targeting skin conditions such as psoriasis and atopic dermatitis. By investing heavily in research and development, Almirall ensures its pipeline remains robust with promising drug candidates and innovative therapies that can meet the unmet needs of dermatology patients. This focus gives them a strategic edge, allowing them to leverage their scientific expertise and deliver state-of-the-art solutions to the market. The financial health of Almirall thrives on a clear business model that involves both direct sales and strategic partnerships. Through collaborations with other pharmaceutical giants and dynamic distribution networks, the company expands its reach beyond Europe, tapping into the American and Asian markets as well. Licensing agreements and co-development partnerships are key to its financial strategy, effectively allowing Almirall to maximize its intellectual property while sharing risks and costs. This multi-pronged approach ensures a steady revenue stream from both its branded products and its generics division, which supplements the overall profitability and sustainability of the company. As Almirall continues to navigate the competitive landscape of the pharma industry, its resilience and adaptability underscore its enduring legacy.

ALM Intrinsic Value
10.81 EUR
Undervaluation 25%
Intrinsic Value
Price

See Also

What is Almirall SA's Inventory?
Inventory
167.1m EUR

Based on the financial report for Sep 30, 2024, Almirall SA's Inventory amounts to 167.1m EUR.

What is Almirall SA's Inventory growth rate?
Inventory CAGR 10Y
6%

Over the last year, the Inventory growth was 3%. The average annual Inventory growth rates for Almirall SA have been 10% over the past three years , 10% over the past five years , and 6% over the past ten years .

Back to Top